Literature DB >> 8651643

A beta-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome.

C M Gomez1, R Maselli, J Gammack, J Lasalde, S Tamamizu, D R Cornblath, M Lehar, M McNamee, R W Kuncl.   

Abstract

Point mutations in the genes encoding the acetylcholine receptor (AChR) subunits have been recognized in some patients with slow-channel congenital myasthenic syndromes (CMS). Clinical, electrophysiological, and pathological differences between these patients may be due to the distinct effects of individual mutations. We report that a spontaneous mutation of the beta subunit that interrupts the leucine ring of the AChR channel gate causes an eightfold increase in channel open time and a severe CMS characterized by severe endplate myopathy and extensive remodeling of the postsynaptic membrane. The pronounced abnormalities in neuromuscular synaptic architecture and function, muscle fiber damage and weakness, resulting from a single point mutation are a dramatic example of a mutation having a dominant gain of function and of hereditary excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651643     DOI: 10.1002/ana.410390607

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

Review 1.  Inherited and experimentally induced changes in gating kinetics of muscle nicotinic acetylcholine receptor.

Authors:  C Bouzat; F J Barrantes
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

2.  Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit.

Authors:  M Milone; H L Wang; K Ohno; T Fukudome; J N Pruitt; N Bren; S M Sine; A G Engel
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome.

Authors:  Jason S Groshong; Melissa J Spencer; Bula J Bhattacharyya; Elena Kudryashova; Bhupinder P S Vohra; Roberto Zayas; Robert L Wollmann; Richard J Miller; Christopher M Gomez
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 4.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

5.  Mutation causing autosomal dominant nocturnal frontal lobe epilepsy alters Ca2+ permeability, conductance, and gating of human alpha4beta2 nicotinic acetylcholine receptors.

Authors:  A Kuryatov; V Gerzanich; M Nelson; F Olale; J Lindstrom
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

6.  Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms.

Authors:  Christopher M Gomez; Ricardo A Maselli; Bhupinder P S Vohra; Manuel Navedo; Joel R Stiles; Pierre Charnet; Kelly Schott; Legier Rojas; John Keesey; Anthony Verity; Robert W Wollmann; Jose Lasalde-Dominicci
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

7.  Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship.

Authors:  Rawiphan Witoonpanich; Teeratorn Pulkes; Charungthai Dejthevaporn; Praphan Yodnopklao; Pirada Witoonpanich; Suppachok Wetchaphanphesat; Joan M Brengman; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-03       Impact factor: 4.296

8.  Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction.

Authors:  C M Gomez; R Maselli; J E Gundeck; M Chao; J W Day; S Tamamizu; J A Lasalde; M McNamee; R L Wollmann
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

9.  Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.

Authors:  Haipeng Zhu; Gary E Grajales-Reyes; Vivianette Alicea-Vázquez; Jose G Grajales-Reyes; KaReisha Robinson; Peter Pytel; Carlos A Báez-Pagán; Jose A Lasalde-Dominicci; Christopher M Gomez
Journal:  Exp Neurol       Date:  2014-10-23       Impact factor: 5.330

10.  Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals.

Authors:  Haipeng Zhu; Bula Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.